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Similar to depression, anxiety is common after acute coronary syndromes (ACS), and is an
independent predictor of worse outcomes.1–3 Yet, post-ACS psychological interventions
have focused on treating depression. We previously reported that an enhanced depression
care intervention involving patient preference for problem-solving therapy (PST),
antidepressant medications, or both followed by stepped care according to treatment
response was effective at reducing depressive symptoms after ACS with an effect size of
0.59 SD.4 We report here the independent effect of this intervention on anxiety.
The trial design is described elsewhere.5 Briefly, hospitalized ACS patients who were
persistently depressed (Beck Depression Inventory (BDI)6 score ≥10 within 1-week of
hospitalization and again 3 months later) were recruited from 5 US hospitals between 2005
and 2008 and randomized to enhanced depression care or to usual care on a 1:1 basis.
Exclusion criteria were alcohol or drug dependency; dementia; psychosis or bipolar
disorder; terminal illness; unavailability for follow-up; BDI score of ≥45; or suicidality. The
institutional review boards at all institutions approved the protocol, and all participants
provided written informed consent.
Enhanced depression care consisted of patient preference for brief problem focused
psychotherapy (i.e., PST) and/or pharmacotherapy and stepped-care in which symptom
severity was reviewed every 8 weeks and treatment was augmented according to
predetermined decision rules. Usual care was defined by the patient’s treating physician(s).
Anxiety and depressive symptoms were assessed within 1-week of hospitalization, and at 3,
5, 7, and 9 months. Anxiety was measured using the 7-item anxiety subscale of the Hospital
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Anxiety and Depression Scale (HADS-A).7 Depressive symptoms were assessed by the
BDI.6 Outcome assessors were blinded to group assignment.
Given the low number and apparent randomness of missing assessments (Little’s MCAR χ2
= 13.97, p=0.12), mixed effects regression was used to generate estimates of treatment
effects on anxiety from month 3 to 9 and t-test to assess the differential change in anxiety
between groups (group × time interaction). Analyses were performed using SAS statistical
software (version 9.2; SAS Institute Inc, Cary, NC).
The mean age of patients in the trial was 60.1 SD 10.6 years and 54% were women.
Enhanced and usual care patients were similar on demographic and baseline medical
variables,4 on HADS-A score at baseline and 3 months (see Table), and in the percent with
HADS-A in a range above normal (HADS-A>7; 61% vs 60%, respectively).
At 9 months, enhanced care patients showed a significant decrease in HADS-A compared to
the 3 month pre-RCT assessment (−2.51; 95% CI, −3.77 to −1.26; p<.001) whereas there
was no significant change in usual care patients (0.13; 95% CI, −0.74 to 1.01; p=0.76),
consistent with an effect size of enhanced care on anxiety of 0.53 (Table). Change in HADS-
A was moderately correlated with change in BDI (Pearson’s r = 0.44, p<.001). Controlling
for depression, the effect of enhanced care on anxiety was decreased by about 1 point, but
remained significant (mean group difference, −1.40; 95%CI −2.62 to −0.24; p=0.02). A
subgroup analysis suggested a benefit of enhanced care on anxiety in women but not men
(see Table).
These results demonstrate that enhanced depression care involving patient treatment
preference of PST and/or antidepressant medications followed by stepped care has collateral
benefits on anxiety in post-ACS patients. Symptoms of anxiety are common after ACS, can
decrease treatment adherence,8,9 lower quality of life,10 and contribute to worse
cardiovascular prognosis.2 Yet, similar to depression, anxiety is often not assessed after
ACS and patients with elevated anxiety often go untreated.11 Thus the current findings
demonstrate one viable approach to improving care for anxious post-ACS patients.
The use of PST may have contributed to the collateral benefit of the intervention on anxiety.
PST is a patient-directed as opposed to disease-focused therapy in which patients are taught
how to systematically evaluate and address individual psychosocial problems of their
choosing. Interestingly, over 60% of enhanced care patients initially chose PST over
antidepressant medications.4
Subgroup analysis showed an effect on anxiety for women but not men. Prior trials of
enhanced depression care have been mixed with some finding gender effects in which men
benefit more than women,12 and others not.4,13 To our knowledge, no prior trials have
reported an interaction between gender and anxiety treatment in cardiovascular populations.
If our finding is replicated, then future anxiety interventions may be more successful if
tailored according to gender.
The secondary nature of the current analyses and sample selection (for depression vs.
anxiety) limit interpretations that can be made, as does the use of HADS-A as a measure of
anxiety in place of a diagnostic psychiatric interview. While an elevated HADS-A score has
been associated with clinical diagnoses, anxiety disorders are heterogeneous and individual
disorders may confer differing risks on post-ACS prognosis.14 Nevertheless, elevated
anxiety symptoms have been associated with a worse cardiac prognosis in prior studies.1
Another limitation is that the comparison group was usual care rather than placebo/active
control. Thus, we did not account for nonspecific effects of treatment on anxiety. Finally, 12
of the 80 patients randomized to treatment never received the intervention; this highlights
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the importance of considering the availability and acceptability of psychological
interventions in post-ACS patients.
In conclusion, future interventions to reduce psychological distress after ACS should assess
their effectiveness on both depression and anxiety symptoms. Those interventions with
pleiotropic effects on both anxiety and depression may be best suited to not only improve
quality of life in ACS survivors, but potentially, to reduce the risk of psychological distress
on adverse cardiovascular outcomes. Future trials should consider whether to target
depressed patients, alone, or to broaden enrollment criteria to include patients with
depression and/or anxiety after ACS.15 Although the intervention reduced anxiety symptoms
compared to usual care, 42% of intervention participants had persistently elevated anxiety
symptoms (HADS-A >7) at 9 months. Accordingly, post-ACS patients with combined
anxiety and depressive symptoms may benefit from a sequential approach in which anxiety
symptoms are monitored alongside depressive symptoms, and are targeted by alternating
treatment strategies (psychotherapy and pharmacotherapy), depending on the individual
history, course, and severity of the patients’ symptoms and symptom profiles.16
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Table
Reduction in Anxiety Symptoms 0, 3 and 9 Months after Acute Coronary Syndrome*
Variable
Intervention v Usual care
Usual Care Group
(n=77)
Intervention Group (n=80) Between-group difference P
Anxiety score at 0 mo 7.53 (6.41 to 8.66) 7.68 (6.57 to 8.79) −0.14 (−1.72 to 1.43) 0.86
Anxiety score at 3 mo (pre-RCT
assessment)
8.29 (7.27 to 9.31) 8.87 (7.97 to 9.77) −0.57 (−1.92 to 0.77) 0.40
Anxiety score at 9 mo 8.35 (7.19 to 9.51) 6.70 (5.75 to 7.64) 1.65 (0.17 to 3.13) 0.03
Change in anxiety score (3 – 9 months) –
overall
0.13 (−0.74 to 1.01) −2.38 (−3.29 to −1.48) −2.51 (−3.77 to 1.26) <.001
Change in anxiety score (3 – 9 months) –
overall, adjusting for depressive symptoms
0.79 (−0.04 to 1.63) −0.64 (−1.54 to 0.26) −1.43 (−2.62 to −0.24) 0.02
 Women only (n= 84) 1.33 (0.10 to 2.56) −1.27 (−2.61 to 0.06) −2.60 (−4.34 to −0.86) 0.004
 Men only (n=73) 0.18 (−0.92 to 1.28) 0.11(−1.09 to 1.30) −0.07 (−1.66 to 1.51) 0.93
*
The anxiety scores at 0, 3 and 9 months are presented as mean (95% confidence interval). The change scores (95% confidence interval) for each
group are parameter estimates for the dummy coded pre-post variable from the mixed effects regression models and the between group differences
(95% confidence interval) in change are the parameter estimates for the group x pre-post interaction from the mixed effects regression analysis.
Anxiety was assessed using the Hospital Anxiety and Depression Scale.7
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